Last reviewed · How we verify
Discontinuation of Azathioprin — Competitive Intelligence Brief
marketed
Immunology
Small molecule
Live · refreshed every 30 min
Target snapshot
Discontinuation of Azathioprin (Discontinuation of Azathioprin) — University of Zurich. Discontinuation of azathioprine involves the cessation of an immunosuppressive drug that inhibits purine synthesis, thereby reducing the suppression of T and B lymphocyte proliferation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Discontinuation of Azathioprin TARGET | Discontinuation of Azathioprin | University of Zurich | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Discontinuation of Azathioprin CI watch — RSS
- Discontinuation of Azathioprin CI watch — Atom
- Discontinuation of Azathioprin CI watch — JSON
- Discontinuation of Azathioprin alone — RSS
Cite this brief
Drug Landscape (2026). Discontinuation of Azathioprin — Competitive Intelligence Brief. https://druglandscape.com/ci/discontinuation-of-azathioprin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab